PROMOMED DM LLC exchange bonds are now on the stock market of high-tech innovative companies
Promomed 04 March 2021
On March 4, 2021, Moscow Exchange PJSC included bonds of PROMOMED DM LLC (MOEX: RU000A102LB5) in the listing of the Innovation and Investment Market (IIM) sector. The decision was made in accordance with the Rules of the trading platform and makes the company's bonds even more attractive to a wide range of investors, exempting them from paying personal income tax on transactions with these securities.
The inclusion of exchange-traded bonds in the IIM quotation lists indicates not only the strategic importance of the issuer for the state and the pharmaceutical industry, but also the company's compliance with strict requirements for corporate governance and the quality of information disclosure.
In addition, presence of a company in the IIM listing confirms that it uses innovative technologies and approaches in activities and invests in high-tech projects. Finally, according to the rules of the trading platform, if an exchange-traded instrument from the IIM list is in continuous possession for at least 1 year, it is exempt from personal income tax. This is an additional argument for investors who have decided to invest in the securities of innovative companies.
The inclusion of exchange-traded bonds in the IIM quotation lists indicates not only the strategic importance of the issuer for the state and the pharmaceutical industry, but also the company's compliance with strict requirements for corporate governance and the quality of information disclosure.
In addition, presence of a company in the IIM listing confirms that it uses innovative technologies and approaches in activities and invests in high-tech projects. Finally, according to the rules of the trading platform, if an exchange-traded instrument from the IIM list is in continuous possession for at least 1 year, it is exempt from personal income tax. This is an additional argument for investors who have decided to invest in the securities of innovative companies.
According to Andrey Mladentsev, PROMOMED's Chief Executive Officer, the company will continue to work on realizing the scientific and production potential to produce effective and high-quality products that preserve the health of millions of people in Russia. «This is what makes PROMOMED an investment-attractive company for investors interested in obtaining a stable coupon income,» he says.
IIM of the Moscow Exchange was established in 2009 and is a trading platform for high-tech, innovative and dynamically developing companies. Interest-bearing non-convertible uncertificated exchange-traded bonds backed by collateral and collective safe custody of the 001P-01 series of PROMOMED DM LLC are included in the «Third level» section of the list of securities admitted to circulation on the IIM.
The investment program of the Promomed Group is focused on the development and production of active pharmaceutical substances and finished dosage forms, the construction of new laboratories and workshops. In the near future, the company plans to focus on the creation of innovative antiviral, antibacterial, endocrinological and cancer drugs.
IIM of the Moscow Exchange was established in 2009 and is a trading platform for high-tech, innovative and dynamically developing companies. Interest-bearing non-convertible uncertificated exchange-traded bonds backed by collateral and collective safe custody of the 001P-01 series of PROMOMED DM LLC are included in the «Third level» section of the list of securities admitted to circulation on the IIM.
The investment program of the Promomed Group is focused on the development and production of active pharmaceutical substances and finished dosage forms, the construction of new laboratories and workshops. In the near future, the company plans to focus on the creation of innovative antiviral, antibacterial, endocrinological and cancer drugs.
